Stock ALT ALTIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-12-04 EST 		5-day change 1st Jan Change
9.850 USD +12.06% Intraday chart for Altimmune, Inc. +12.83% -12.44%
11-15 Altimmune Reports 'Significant' Drop in Inflammatory Lipids With Pemvidutide in Liver Disease Treatment MT
11-15 Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders
12-03
 AQ
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
12-02
 AQ
Altimmune to Participate at Two Upcoming Investor Conferences
11-26
 AQ
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at the Liver Meeting 2024
11-18
 AQ
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
11-15
 AQ
Altimmune : Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer Form 8 K
11-12
 PU
Altimmune : Announces Third Quarter 2024 Financial Results and Provides a Business Update Form 8 K
11-12
 PU
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
11-12
 AQ
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11-11
 AQ
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
11-11
 AQ
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
11-07
 AQ
Altimmune to Participate at Two Upcoming Investor Conferences
11-06
 AQ
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
11-04
 AQ
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024
10-16
 AQ
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
10-15
 AQ
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
10-01
 AQ
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
09-30
 AQ
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
09-10
 AQ
Poster: Pemvidutide Preserves Lean Body Mass During Weight Loss in Patients with Overweight and Obesity: Results of a Phase 2 MRI Based Body Composition Sub Study
09-09
 PU
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
09-03
 AQ
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
08-08
 AQ
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
08-01
 AQ
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease in Journal of Hepatology
07-26
 AQ
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
07-25
 AQ
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)
07-03
 BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALT Stock
  4. News Altimmune, Inc.
  5. Press Releases
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition